cognitive cybersecurity intelligence

News and Analysis

Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought?

Despite concerns about the efficacy and safety of checkpoint inhibitors, many biotech companies are advancing them in clinical trials to treat cancer. By 2032, the market for these drugs could reach nearly $189.4 billion. While these inhibitors have shown dramatic results in some cancer patients, they only seem to work for a small percentage. As a result, research is shifting towards combining them with other cancer treatments, and exploring potential new inhibitors. These advances are expected to revolutionize cancer care.

Source: www.labiotech.eu –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

Threat Actors Exploiting DevOps Web Servers Misconfigurations To Deploy Malware

Threat Actors Exploiting DevOps Web Servers Misconfigurations To Deploy Malware

A new cryptojacking campaign, led by threat actor JINX-0132, exploits misconfigurations in popular DevOps applications like HashiCorp Nomad and Docker API. By utilizing legitimate tools

Securing Cloud Infrastructure – AWS, Azure, and GCP Best Practices

Securing Cloud Infrastructure – AWS, Azure, and GCP Best Practices

Cloud security is vital for organizations using public cloud services like AWS, Azure, and GCP. This guide outlines technical strategies for implementing robust security practices,

Mastering Intrusion Detection Systems – A Technical Guide

Mastering Intrusion Detection Systems – A Technical Guide

Intrusion Detection Systems (IDS) are vital for cybersecurity, monitoring network traffic and system activities to detect threats. This guide covers IDS architectures, detection methods (signature-based

Deep Dive into Endpoint Security

Deep Dive into Endpoint Security

By 2025, the endpoint security landscape will feature integrated EDR, XDR, and EPP solutions to combat diverse cyber threats. Organizations must adopt Zero Trust architectures